Production (Stage)
Aquestive Therapeutics, Inc.
AQST
$2.35
$0.062.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -26.52% | -12.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -26.52% | -12.37% | |||
| Cost of Revenue | -19.20% | 1.87% | |||
| Gross Profit | -31.02% | -19.31% | |||
| SG&A Expenses | 19.13% | 32.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.37% | 16.55% | |||
| Operating Income | -42.61% | -63.80% | |||
| Income Before Tax | -34.34% | -48.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -34.45% | -48.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.45% | -48.19% | |||
| EBIT | -42.61% | -63.80% | |||
| EBITDA | -43.38% | -64.91% | |||
| EPS Basic | -28.40% | -47.94% | |||
| Normalized Basic EPS | -37.96% | -37.72% | |||
| EPS Diluted | -28.40% | -43.85% | |||
| Normalized Diluted EPS | -37.96% | -37.72% | |||
| Average Basic Shares Outstanding | 4.71% | 0.13% | |||
| Average Diluted Shares Outstanding | 4.71% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||